Profil
Dr Graham Hughes, a chemist by training, has broad-based research, development and commercial experience in the chemical, agrochemical and pharmaceutical industries.
He initially worked for ICI and, whilst Development Manager at their European Headquarters in Brussels, was responsible for the in-house laboratory development and field trials of a wide range of speciality chemicals, with applications in cosmetics, pharmaceuticals and agrochemicals.
He was also Toxicology Liaison Officer for ICI Europa.
As Director of Technical and Regulatory Affairs for Zoecon Corporation (Europe) - a Sandoz subsidiary - he was in overall charge of the technical development of animal health products and agrochemicals, from research through to registration.
Graham Hughes was a co-founder of the company in 1987 and is an acknowledged expert on pharmaceutical outsourcing, having intimate familiarity with all aspects of Contract Research Organisations.
He is Chairman of the Editorial Board of European Pharmaceutical Contractor, and an Editorial Adviser to Global Outsourcing Review.
Ehemalige bekannte Positionen von Graham Hughes
| Unternehmen | Position | Ende |
|---|---|---|
Technomark Investment Management Ltd.
 Technomark Investment Management Ltd. Investment ManagersFinance Technomark Investment Management Ltd. (TIM) is inactive since 2009. Formerly known as Technomark Medical Ventures, TIM is the venture capital arm and a subsidiary of Technomark Consulting Services Ltd., a consulting firm specialized in the pharmaceutical and biotechnology sectors, and the European branch of the US-based Technomark Group USA LLC, headquartered in Research Triangle Park, North Carolina. The group has additional offices in Mumbai, India and in Nanjing, China. The activities of the Technomark group include corporate finance, venture capital and management consulting focused on outsourcing in the pharmaceutical domain. Their clients are large pharmaceutical corporations, contract research organizations, contract manufacturing organizations, investment banks and public entities. Technomark's European branch operates since 1987 in London. TIM originated in 2000 with the backing of Lloyds TSB Development Capital Ltd., the venture capital arm of Lloyds TSB Group plc (LSE: LLOY; NYSE: LYG). The current firm was formally established in 2005 when the group was reorganized. TIM manages a private equity fund focused on the life sciences. | Direktor der Forschung - Eigenkapital | 01.10.2008 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Technomark Investment Management Ltd.
Technomark Investment Management Ltd. Investment ManagersFinance Technomark Investment Management Ltd. (TIM) is inactive since 2009. Formerly known as Technomark Medical Ventures, TIM is the venture capital arm and a subsidiary of Technomark Consulting Services Ltd., a consulting firm specialized in the pharmaceutical and biotechnology sectors, and the European branch of the US-based Technomark Group USA LLC, headquartered in Research Triangle Park, North Carolina. The group has additional offices in Mumbai, India and in Nanjing, China. The activities of the Technomark group include corporate finance, venture capital and management consulting focused on outsourcing in the pharmaceutical domain. Their clients are large pharmaceutical corporations, contract research organizations, contract manufacturing organizations, investment banks and public entities. Technomark's European branch operates since 1987 in London. TIM originated in 2000 with the backing of Lloyds TSB Development Capital Ltd., the venture capital arm of Lloyds TSB Group plc (LSE: LLOY; NYSE: LYG). The current firm was formally established in 2005 when the group was reorganized. TIM manages a private equity fund focused on the life sciences. | Finance |
